Quote:

---

Interesting mouse study in Glioblastoma. A cheap antidepressant helps to keep the cancer cells from multiplying, which greatly slows tumor growth. This research tested 2500 drugs against Glioblastoma.

---

The drug they used was vortioxetine which decreases MAPK, TNF-a and NF-kb. It also increases PPARy. Which would lead to a decrease in inflammation and some factors involved in cancer. Leronlimab affects those factors the same but more likely to a higher degree.

The difference is that vortioxetine promotes an M1 macrophage (inflammatory) to M1 macrophage (anti-inflammatory) shift while leronlimab promotes an M2 to M1 shift while blocking the CCR5 induced inflammation itself. I have seen that M1 to M2 shift in other cancer drugs also. A shift to M2 can help stifle cancer growth to an extent but can hamper the immune system's ability to kill cancer cells. Leronlimab's trick is that it downregulates the inflammatory cancer promoting cytokines by blocking CCR5 but increases the tumor killing macrophages. Better to have a drug that can do both.